Navigation Links
Vitasoy Recorded Healthy Sales Growth for 1H FY2007/2008
Date:11/26/2007

a three-pronged strategy: the launch of single-serve shelf-stable soymilk; enhancement of Vitasoy's leading position in the tofu market, and further development of the ethnic market.

"Our efforts to improve our financial performance in North America will be further strengthened by cost rationalization measures and price revisions on selected products. In spite of the challenges of the market, we believe there is opportunity for Vitasoy USA to grow," Mr. Lo commented.

Business Outlook

Looking ahead, Mr. Lo said, "We will leverage our core competencies and focus on areas we excel in, including product innovation, brand building and cost management, to drive revenue growth and capture larger market shares, amidst the challenges brought by intensifying market competition, inflationary pressure and rising costs of raw materials. We will also explore new business opportunities to create greater long-term shareholder value."

Vitasoy International Holdings Limited is one of the leading manufacturers and distributors of non-carbonated drinks with a base in Hong Kong. Founded in 1940 and with production facilities in Hong Kong, Mainland China, Australia and the United States, Vitasoy currently provides consumers in 42 markets worldwide with over 1,000 stock keeping units (SKU). Over the years, Vitasoy has successfully established a corporate image as "the soy expert". Vitasoy is a constituent of the Morgan Stanley Capital International ("MSCI") Hong Kong Small Cap Index.

For more information, please contact:

Stella Lung, Public Relations Manager

Tel: +852-2468-9644

Fax: +852-2465-1008

Email: pubrel@vitasoy.com

Angela Hui / Paul Sham, Ketchum Hong Kong

Tel: +852-3141-8091 / +852-3141-8068

Fax: +852-2510-8199

Email: angela.hui@knprhk.com / paul.sham@kn
'/>"/>

SOURCE Vitasoy International Holdings Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Vitasoy Promotes the Soy Breast Health Connection
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe)
6. Heart-Healthy Workouts Help Knees, Too
7. Finicky Felines Award Four Stars to New Wellness(R) Healthy Indulgence Everyday Entrees
8. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
9. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
10. On September 7th Local Organizations Partner to Celebrate Healthy Steps
11. September is Healthy Aging Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...hows for the first time how microscopic crystals f.... Located at the ends of cilia tiny cellular hair... crystals play an important role in detecting soun... , Dislodged ear crystals are to blame for the m...smal positional vertigo, the disorder plagues up t...
(Date:12/1/2008)... Breast-Specific Gamma Imaging (BSG...substantially less expensive than,breast magnetic...ty for,detecting breast carcinoma when used in pr... diagnoses, according to findings presented today ... of North America (RSNA). , "According to t...
(Date:12/1/2008)...., Dec. 1 Vapotherm, th...ts, announced today that President and CEO, Robert...alth care conference on Wednesday, December 3rd at... , The conference brings together public and ...ectors to present and discuss trends, advances, ch...
(Date:12/1/2008)...Dec. 1 Welvista is pleased to anno...tis U.S., one of the world,s leading,pharmaceutic...s to the,uninsured through Welvista,s no-cost pre...of 23 sanofi-aventis drugs from the company,s Pati...180 drugs on its formulary for the,uninsured. Inc...
Breaking Medicine News(10 mins):Health News:Can you hear me now? How the inner ear's sensors are made 2Health News:Molecular Breast Imaging Proves Cost-Effective for Presurgical Planning in Patients with Breast Cancer 2Health News:Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured 2
... ban in pubs and clubs across New Zealand have sig...gambling.// The Clubs New Zealand president Brian...%. He also said that this would reduce about $60 m...ous sports and other community groups. Problem Gam...
... research ethics requirements are compromising the...r doctors in this week’s BMJ.// Many ethics commi...ople who respond positively to a letter from their...unity to take part in research – that is, people m...
...th of a zoo animal, an Australian black swan, in G...rus has created shock waves among animal-lovers.//... farm poultry in Germany. Therefore the death of t...oo in eastern Germany has raised fears that animal...
...earchers from Saint Mary's Hospital for Women and ...n otherwise healthy teen girls// that they have a ...ve also noted that white girls had significantly h...d with the non-white counterparts. The study has a...
Other Medicine News:Health News:Research Ethics Requirements Compromising Quality of Health Research 2Health News:Study finds Adolescents Girls Have Lower Levels Of Vitamin-D 2
(Date:11/25/2008)...areness can improve recovery , , Audio and ...ailable on the Mayo Clinic News Blog. Please see t..., ROCHESTER, Minn., Nov. 25 /PRNewswire-USNewsw...roke patients don,t think they,re having a stroke ...l their condition worsens. The findings appear in ...
(Date:11/25/2008)...FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ ...), a biopharmaceutical company focused on,innovat...ll be exploring,strategic alternatives for its pr... Company to focus its resources on the clinical de...te, and to support the initial commercialization o...
(Date:11/24/2008)... Ill., and OSAKA, Japan, Nov. 24 T...y-owned subsidiary, Takeda Global Research & D...t the Arthritis Advisory Committee of the U.S. Foo...he FDA approve febuxostat for the treatment of hy... to zero in favor of approval, with one panel memb...
(Date:11/24/2008)...affirms its innovation leadership and long-term co...TH, N.J., Nov. 24 Scheri...d a clinical update on boceprevir, its lead invest...ently in Phase III development. The company belie...class and best-in-class protease inhibitor for tre...
Breaking Medicine Technology:Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Studies on Urgent 28R 29 PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium 11515 1Studies on Urgent 28R 29 PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium 11515 2The beauty bias 3A Can people love the one they are compatible with 3F 11512 1The beauty bias 3A Can people love the one they are compatible with 3F 11512 2Study finds patients with complex fibroadenomas can avoid surgery 11509 1Study finds patients with complex fibroadenomas can avoid surgery 11509 2Paxonix Recognized for Exemplary Support in New Product Development and Implementation 11506 1Paxonix Recognized for Exemplary Support in New Product Development and Implementation 11506 2
...phoma Reported,Today at ASCO Annual Meeting, PHILA...line plc,announced today long-term efficacy data f...f frontline treatment with the BEXXAR(R),Therapeut...ab) in,76 patients with newly diagnosed advanced f...en was found to induce durable clinical,and molecu...
...07 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) anno...study of Androxal(TM), an oral drug being,develope...h,secondary hypogonadism. Further, Androxal demons... study, compared to,Androgel(R), a cream which is ... Details and Results , This six month, double-blin...
Other Medicine Technology:8-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 2Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 3Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 4Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism 5
This therapeutic system is optimally designed with the patient in mind. As an alternative to surgery and ongoing therapy, SONOCUR Basic provides a low-risk and effective therapy. Plus, the patient re
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm
...e most modern lithotripters available today but al...ng designed for the treatment of the entire spectr...LX can also be employed for a variety of other end...the treatment of gallstones or for orthopeadic ind...
...DICAL is the result of many years of extensive exp...nd the successful implementation of the specific r... extracorporeal shock wave therapy, as has been ou... its compact size and astonishing mobility, which ...
Medicine Products: